FDA Approves AstraZeneca’s CALQUENCE Combo for CLL, SLL
WILMINGTON, DE — AstraZeneca said the U.S. Food and Drug Administration has approved CALQUENCE (acalabrutinib) in combination with venetoclax as a fixed-duration, all-oral treatment for adults with chronic lymphocytic leukemia …
FDA Approves AstraZeneca’s CALQUENCE Combo for CLL, SLL Read More